Radiolabeled liposomes for scintigraphic imaging

• Published in: Progress in lipid research Vol. 39; no. 5; pp. 461 - 475
• Main Authors: Boerman, O.C., Laverman, P., Oyen, W.J.G., Corstens, F.H.M., Storm, G.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2000
• Subjects: Animals; Bacterial Infections - diagnostic imaging; Chelating Agents; Gated Blood-Pool Imaging; Half-Life; Humans; Inflammation - diagnostic imaging; Isotope Labeling; Liposomes - pharmacokinetics; Mice; Mice, Nude; Models, Animal; Neoplasms - diagnostic imaging; Rabbits; Radiopharmaceuticals
• ISSN: 0163-7827; 1873-2194
• DOI: 10.1016/S0163-7827(00)00013-8

Liposomes have been investigated extensively as carriers for drugs in attempts to achieve selective deposition and/or reduced toxicity. Liposomes radiolabeled with gamma emitters such as 67Ga, 111In and 99mTc, can be used for imaging purposes. Liposomes as formulated in the past, are rapidly taken up by cells of the mononuclear phagocyte system (MPS), primarily those located in liver and spleen. The recent development of long-circulating liposomes (LCLs), yielded liposomes that oppose recognition by the MPS. The development of these LCLs with enhanced circulatory half-lives has broadened the potential of liposomes to scintigraphically visualize pathologic processes in vivo. Liposomes have been proposed for tumor imaging, infection imaging and blood pool imaging. Strategies have been developed that allow rapid, easy and efficient labeling of preformed liposomes with 111In and 99mTc. There is now a vast body of preclinical evidence showing that LCLs can be used to image a wide variety of tumors as well as inflammatory lesions. The first studies in patients show that radiolabeled liposomes can image tumor and inflammatory lesions with good sensitivity and good specificity. Here, the present status of liposome-based radiopharmaceuticals for scintigraphic application is reviewed.